Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis C in Spain].

Miguel Bruguera1, Xavier Forns

  • 1Servicio de Hepatología, Institut de Malalties Digestives i Metabòliques, Hospital Clínic, Barcelona, España. bruguera@clinic.ub.es

Medicina Clinica
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of drug-induced liver injury in the urban primary care setting.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.

The Lancet regional health. Europe·2026
Same author

Early hepatitis B and delta virus kinetics in patients undergoing liver transplantation.

Scientific reports·2026
Same author

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

Journal of hepatology·2026
Same author

Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Clinical features and management for CDK4/6 inhibitor-DILI.

JHEP reports : innovation in hepatology·2026
Same journal

Effectiveness of cardiac Holter monitoring for more than four weeks for the detection of occult atrial fibrillation in embolic stroke of undetermined source.

Medicina clinica·2026
Same journal

Artificial intelligence in surgical training and education: a narrative review.

Medicina clinica·2026
Same journal

Treatment of phantom limb syndrome with ketamine.

Medicina clinica·2026
Same journal

Comment on "Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis".

Medicina clinica·2026
Same journal

Limitations in the interpretation of thyroid function tests.

Medicina clinica·2026
Same journal

Cerebrotendinous xanthomatosis without neurological manifestations: An atypical form with normal cholestanol levels.

Medicina clinica·2026
See all related articles

Hepatitis C virus (HCV) infection in Spain affects an estimated 480,000–760,000 people, with higher rates in specific groups. Early screening and treatment are crucial for managing advanced liver disease.

Area of Science:

  • Hepatology and Infectious Diseases
  • Public Health Epidemiology
  • Viral Hepatitis Research

Context:

  • Spain exhibits medium endemicity for Hepatitis C virus (HCV) infection, with prevalence ranging from 1.6% to 2.6%.
  • HCV prevalence increases with age from 30 years, disproportionately affecting prisoners, drug users, and certain immigrant populations.
  • Historically, transmission in Spain occurred via blood transfusions, IV drug use, and medical procedures.

Purpose:

  • To analyze the epidemiological landscape of Hepatitis C virus infection in Spain.
  • To identify high-risk populations and transmission routes.
  • To assess the impact of public health interventions and future challenges in HCV management.

Summary:

  • An estimated 480,000 to 760,000 individuals in Spain are infected with HCV, with significant variations across regions and demographics.

Related Experiment Videos

  • While new infections have decreased due to harm reduction and improved blood safety, nosocomial and vertical transmissions remain concerns.
  • Despite reduced incidence, an increase in advanced HCV liver disease is anticipated due to delayed diagnoses.

    • Impact:

    • Public health initiatives have reduced HCV incidence, but challenges remain in identifying and treating undiagnosed cases.
    • Increased screening in primary care settings can lead to earlier treatment, improving patient outcomes and reducing healthcare costs.
    • Effective management of chronic Hepatitis C is vital for mitigating long-term health and economic burdens in Spain.